We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+12.8%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$237M
AUM Growth
-$4.18M
(-1.7%)
Cap. Flow
-$18.3M
Cap. Flow
% of AUM
-7.71%
Top 10 Holdings %
Top 10 Hldgs %
7.93%
Holding
416
New
61
Increased
247
Reduced
47
Closed
61
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$1.78M |
| 2 |
EOG Resources
EOG
|
+$1.78M |
| 3 |
ConocoPhillips
COP
|
+$1.72M |
| 4 |
Imperial Oil
IMO
|
+$1.64M |
| 5 |
Vornado Realty Trust
VNO
|
+$1.59M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ryman Hospitality Properties
RHP
|
+$2.57M |
| 2 |
Western Midstream Partners
WES
|
+$2.52M |
| 3 |
INN
Summit Hotel Properties
INN
|
+$2.43M |
| 4 |
Brookfield Renewable
BEPC
|
+$2.38M |
| 5 |
Grupo Aeroportuario del Pacifico
PAC
|
+$2.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.46% |
| 2 | Real Estate | 18.03% |
| 3 | Energy | 13.68% |
| 4 | Materials | 11.34% |
| 5 | Utilities | 10.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Omeros
OMER
$821M
| $733K | 0.31% |
41,200
+1,132
| +3% | +$22K |
|
102
United Therapeutics
UTHR
$26.3B
| $732K | 0.31% |
4,376
+124
| +3% | +$20.7K |
|
103
Enanta Pharmaceuticals
ENTA
$370M
| $726K | 0.31% |
14,721
+400
| +3% | +$20K |
|
104
Vanda Pharmaceuticals
VNDA
$314M
| $720K | 0.3% |
47,914
+1,312
| +3% | +$21.2K |
|
105
Biogen
BIIB
$29.5B
| $713K | 0.3% |
2,550
+68
| +3% | +$18.3K |
|
106
Nektar Therapeutics
NKTR
$2.41B
| $710K | 0.3% |
2,365
+65
| +3% | +$20.2K |
|
107
Nuveen Credit Strategies Income Fund
JQC
$702M
| $698K | 0.29% |
107,355
+18,827
| +21% | +$121K |
|
108
Exelixis
EXEL
$14B
| $687K | 0.29% |
30,432
+830
| +3% | +$18.7K |
|
109
Amgen
AMGN
$203B
| $684K | 0.29% |
2,750
+98
| +4% | +$23.4K |
|
110
Gilead Sciences
GILD
$162B
| $684K | 0.29% |
10,578
+407
| +4% | +$26.2K |
|
111
Carlyle Secured Lending
CGBD
$710M
| $681K | 0.29% |
51,567
-1,208
| -2% | -$14.6K |
|
112
Theravance Biopharma
TBPH
$874M
| $671K | 0.28% |
32,871
+905
| +3% | +$17.2K |
|
113
Alnylam Pharmaceuticals
ALNY
$37.2B
| $667K | 0.28% |
4,721
+134
| +3% | +$20.2K |
|
|
SAGE
114
DELISTED
Sage Therapeutics
SAGE
| $663K | 0.28% |
8,852
+241
| +3% | +$19.8K |
|
|
XLRN
115
DELISTED
Acceleron Pharma
XLRN
| $652K | 0.28% |
4,810
+129
| +3% | +$16.7K |
|
116
Neurocrine Biosciences
NBIX
$17.7B
| $651K | 0.28% |
6,692
+180
| +3% | +$18.9K |
|
|
FPRX
117
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $645K | 0.27% |
17,112
+302
| +2% | +$7.53K |
|
118
BioNTech
BNTX
$23B
| $631K | 0.27% |
5,779
+158
| +3% | +$16.8K |
|
119
Halozyme
HALO
$9.66B
| $623K | 0.26% |
14,954
+411
| +3% | +$18.8K |
|
120
ImmunityBio
IBRX
$7.32B
| $614K | 0.26% |
25,850
+462
| +2% | +$12K |
|
|
ALXN
121
DELISTED
Alexion Pharmaceuticals
ALXN
| $613K | 0.26% |
4,009
+115
| +3% | +$17.8K |
|
122
Barings BDC
BBDC
$868M
| $606K | 0.26% |
60,759
-19,706
| -24% | -$187K |
|
123
Travere Therapeutics
TVTX
$5.27B
| $597K | 0.25% |
+23,907
| New | +$661K |
|
|
GBT
124
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $597K | 0.25% |
14,654
+400
| +3% | +$18.4K |
|
|
ESPR
125
DELISTED
Esperion Therapeutics
ESPR
| $593K | 0.25% |
21,157
+581
| +3% | +$17.1K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q1 2021 Portfolio in Review
As of Q1 2021, Virtus ETF Advisers held 416 positions worth $237M, down 1.7% from $241M the previous quarter. Its ten largest holdings account for 7.9% of the portfolio.
Virtus ETF Advisers withdrew a net $18.3M in Q1 2021, closing 61 positions and reducing 47 holdings. Its most notable exit was Ryman Hospitality Properties, an estimated $2.57M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 30% of assets, up from 30% a quarter earlier, followed by Real Estate and Energy.
Against the trend, Virtus ETF Advisers opened a new position in Pioneer Natural Resource Co. worth $1.99M.
- Virtus ETF Advisers's largest Q1 2021 buy was Pioneer Natural Resource Co.: 12,538 shares worth $1.99M.
- Virtus ETF Advisers added most to Oaktree Specialty Lending in Q1 2021, an estimated $216K increase.
- Virtus ETF Advisers's biggest Q1 2021 reduction was Avient, cutting an estimated $916K.
- Virtus ETF Advisers fully exited Ryman Hospitality Properties in Q1 2021, selling an estimated $2.57M.
- Virtus ETF Advisers's ten largest holdings make up 7.9% of its $237M portfolio in Q1 2021.
- Virtus ETF Advisers opened 61 new positions and closed 61 in Q1 2021.
- Virtus ETF Advisers's portfolio value fell 1.7% quarter-over-quarter to $237M.
Based on Virtus ETF Advisers's 13F filing for Q1 2021, filed 17 May 2021.